

Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO)

Dana Lucia Stanculeanu¹, Daniela Mosoiu², Alecu Mihnea³, Laurentiu Simion³

¹Medical Oncology First Department, „Prof. Dr. Al. Trestioreanu” Institute of Oncology, Bucharest, Romania

²Faculty of Medicine, Transilvania University, Braşov, Romania

³First Surgical Clinic, „Prof. Dr. Al. Trestioreanu” Institute of Oncology Bucharest, Romania

Abstract

Ovarian cancer represents the 4-th reason of cancer related death in women, the majority of patients being diagnosed in advanced stages of the disease, (III-IV). The loco-regional advanced ovarian cancer should be considered a chronic disease, with multiple evolutionary relapses and where the adjuvant treatment is mandatory. The treatment of the disease is multidisciplinary and the oncologist is the centerpiece.

Key words: ovarian cancer, Bevacizumab, BRCA-1, BRCA-2, Olaparib, Clinical trials